scispace - formally typeset
Open AccessJournal ArticleDOI

Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection.

Reads0
Chats0
TLDR
Combinations of medical and behavioral interventions should be used to promote persons with substance use disorders engagement into and adherence with direct-acting antiviral-based treatment approaches, which have the potential to improve adherence and consequently treatment efficacy.
Abstract
Direct-acting antivirals for hepatitis C virus infection may revolutionize treatment among persons with substance use disorders. Despite persons with substance use disorders having the highest hepatitis C virus prevalence and incidence, the vast majority have not engaged into care for the infection. Previously, interferon-based treatments, with substantial side effects and the propensity to exacerbate mental health conditions, were major disincentives to pursuit of care for the infection. Direct-acting antivirals with viral eradication rates of >90%, significantly improved side effect profiles, and shorter treatment duration are dramatic improvements over prior treatment regimens that should promote widespread hepatitis C virus care among persons with substance use disorders. The major unmet need is strategies to promote persons with substance use disorders engagement into care for hepatitis C virus. Although physical integration of treatment for substance use and co-occurring conditions has been widely advocated, it has been difficult to achieve. Telemedicine offers an opportunity for virtual integration of behavioral and medical treatments that could be supplemented by conventional interventions such as hepatitis C virus education, case management, and peer navigation. Furthermore, harm reduction and strategies to reduce viral transmission are important to cease reinfection among persons with substance use disorders. Widespread prescription of therapy for hepatitis C virus infection to substance users will be required to achieve the ultimate goal of global virus elimination. Combinations of medical and behavioral interventions should be used to promote persons with substance use disorders engagement into and adherence with direct-acting antiviral-based treatment approaches. Ultimately, either physical or virtual colocation of hepatitis C virus and substance use treatment has the potential to improve adherence and consequently treatment efficacy.

read more

Citations
More filters
Journal ArticleDOI

Update on global epidemiology of viral hepatitis and preventive strategies

TL;DR: The current global prevalence status of viral hepatitis is presented, potential elimination strategies are examined and potential strategies to reduce infection control measures are examined.
Journal ArticleDOI

Integrated, Co-located, Telemedicine-based Treatment Approaches for Hepatitis C Virus Management in Opioid Use Disorder Patients on Methadone.

TL;DR: HCV management via telemedicine integrated into an OST program is a feasible model with excellent virologic effectiveness and psychosocial and demographic variables can assist in identification of subgroups with a propensity or aversion to pursue HCV treatment.
Journal ArticleDOI

Integrated models of care for people who inject drugs and live with hepatitis C virus: A systematic review.

TL;DR: Investigation of the impacts of co-location of HCV and substance use services on engagement in the HCV cascade of care among adult PWID indicated that overall integrated care resulted in improved engagement in HCV care, but the quality of evidence was predominantly low to moderate.
Journal ArticleDOI

The Current and Future Use of Telemedicine in Infectious Diseases Practice.

TL;DR: This narrative review presents current and future uses of telemedicine in the prevention, diagnosis, treatment, stewardship, and management of infectious disease.
Journal ArticleDOI

Conceptualising access in the direct-acting antiviral era: An integrated framework to inform research and practice in HCV care for people who inject drugs

TL;DR: This framework is offered as an organising device for observational research, intervention, and implementation science to expand access to HCV care in this vulnerable population and demonstrates its utility for specifying research questions and intervention targets across multiple levels of influence.
References
More filters
Journal ArticleDOI

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

TL;DR: In patients with chronic hepatitis C, once-weekly peginterferon alfa-2a plus ribavirin was tolerated as well as interferonAlfa- 2b plus Ribavirin and produced significant improvements in the rate of sustained virologic response, as compared with interfer on alfa -2b plus ribvirin or pegin terferonalfa-3a alone.
Journal ArticleDOI

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

TL;DR: In patients with chronic hepatitis C, the most effective therapy is the combination of peginterferon alfa-2b 1.5 microg/kg per week plus ribavirin, and this randomised trial found that the benefit is mostly achieved in patients with HCV genotype 1 infections.
Journal ArticleDOI

Global epidemiology of hepatitis C virus infection

TL;DR: Because there is no vaccine and no post-exposure prophylaxis for HCV, the focus of primary prevention efforts should be safer blood supply in the developing world, safe injection practices in health care and other settings, and decreasing the number of people who initiate injection drug use.
Journal ArticleDOI

Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

TL;DR: Telaprevir with peginterferon-ribavirin was associated with significantly improved rates of sustained virologic response in patients with HCV genotype 1 infection who had not received previous treatment, with only 24 weeks of therapy administered in the majority of patients.
Journal ArticleDOI

Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies.

TL;DR: The natural history of cirrhosis is outlined, the model for end stage liver disease (MELD) has replaced the Child–Pugh score in the United States for prioritizing liver donor allocation and a systematic review of the literature regarding predictors of mortality in cirrhotic patients is reported on.
Related Papers (5)